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A B S T R A C T   
Background: Treatment resistant depression (TRD) is diagnosed when patients experiencing a major depressive 
episode fail to respond to ≥2 treatments. Along with substantial indirect costs, patients with TRD have higher 
healthcare resource utilization (HCRU) than other patients with depression. However, research on the economic 
impact of this HCRU, and differences according to response to treatment, is lacking. 
Methods: This multicenter, observational study documented HCRU among patients with TRD in European clinical 
practice initiating new antidepressant treatments. Data regarding access to outpatient consultations and other 
healthcare resources for the first 6 months, collected using a questionnaire, were analyzed qualitatively ac-
cording to response and remission status. The economic impact of HCRU, estimated using European costing data, 
was analyzed quantitatively. 
Results: Among 411 patients, average HCRU was higher in non-responders, attending five times more general 
practitioner (GP) consultations and spending longer in hospital (1.7 versus 1.1 days) than responders. Greater 
differences were observed according to remission status, with non-remitters attending seven times more GP 
consultations and spending approximately three times longer in hospital (1.7 versus 0.6 days) than remitters. 
Consequently, the estimated economic impacts of non-responders and non-remitters were significantly greater 
than those of responders and remitters, respectively. 
Limitations: Key limitations are small cohort size, absence of control groups and generalizability to different 
healthcare systems. 
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Conclusion: Patients with TRD, particularly those not achieving remission, have considerable HCRU, with asso-
ciated economic impact. The costs of unmet TRD treatment needs are thus substantial, and treatment success is 
fundamental to reduce individual needs and societal costs.   
1. Introduction 
Major depressive disorder (MDD) is a common mood disorder asso-
ciated with significant morbidity and mortality, and with elevated risk 
of suicide (Vos et al., 2020; Cavanagh et al., 2003). Of patients with 
MDD, approximately 10–30% will have treatment resistant depression 
(TRD) (Jaffe et al., 2019; Rush et al., 2006; Al-Harbi, 2012; Voineskos 
et al., 2020), defined as the presence of a major depressive episode 
(MDE) that fails to respond to a minimum of two different antidepres-
sants, given in adequate dose and duration (European Medicines 
Agency, 2013). Treatments for MDD include medication, psychother-
apy, neurostimulation therapies and combinations of these (European 
Medicines Agency, 2013). The effectiveness of a treatment is determined 
according to depression symptoms after treatment, with response 
referring to reduction of depression symptoms beyond a pre-defined 
study-specific cut off, while remission is defined as achieving a low 
threshold of depression symptoms and is typically more stringently 
defined than response (Rush et al., 2006). Patients with MDD who 
achieve remission are less likely to relapse, and more likely to show 
long-term stability and improved psychosocial functioning, thereby 
supporting remission as the goal of MDD treatment (Mendlewicz, 2008; 
Rush et al., 2006). Any treatments approved for use in MDD can be 
applied to treat TRD and clinical management may thus also comprise 
various combinations of antidepressant and non-antidepressant medi-
cations, as well as non-pharmacological therapies (Bennabi et al., 2019; 
European Medicines Agency, 2013; Voineskos et al., 2020). Regarding 
European-wide approval, a single pharmacological treatment, esket-
amine nasal spray (in combination with a selective serotonin reuptake 
inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) 
was the first treatment approved specifically for TRD, as defined above 
(European Medicines Agency, 2013; Mahase, 2019). However, there is 
no consensus on treatment pathways for TRD and evidence suggests 
there is wide variation between and within countries in Europe (Mac-
Queen et al., 2017). 
Previous literature indicates that patients with TRD have higher 
levels of healthcare resource utilization (HCRU) than both MDD patients 
without TRD and the general population, highlighting a clear unmet 
need in the treatment of this condition (Jaffe et al., 2019; Johnston et al., 
2019; Sussman et al., 2019). In a European study of MDD, patients with 
TRD were consistently found to have significantly greater HCRU than 
patients without TRD (Jaffe et al., 2019). In another study conducted in 
the US, annual healthcare payments for patients with TRD in the year 
following their diagnosis were on average US$3000 higher than those 
without TRD (Sussman et al., 2019). Evidence further suggests that as 
the number of treatment failures increases, the direct and indirect 
healthcare costs for patients with TRD rise, while their health-related 
quality of life (HRQoL) declines (Johnston et al., 2019). Importantly, a 
recent study of a TRD patient cohort in France also found that HCRU 
reduces as patients achieve response, remission and recovery (Yrondi 
et al., 2020). 
This paper presents data from the Treatment Resistant Depression 
Cohort in Europe study (54135419DEP4001), a prospective, multi-
center, non-interventional, observational study conducted to collect 
real-world data from adult patients with TRD being treated in routine 
clinical practice across a sample of countries in Europe. Overall, the 
objectives of the study were to describe: the socio-demographic and 
disease-related characteristics of patients with TRD in a sample of 
representative European countries; the social and economic burden 
associated with TRD in a real-world setting; the naturalistic treatment 
patterns and associated clinical outcomes in TRD in routine clinical 
practice; and the HCRU of patients in the cohort. Data to support the first 
three objectives are described in two previously published papers 
(Heerlein et al., 2021a, 2021b). 
As reported by Heerlein et al. (2021a), the mean duration of the 
current MDE at baseline exceeded 2.5 years. Coupled with high Mont-
gomery-Åsberg Depression Rating Scale (MADRS) scores, this indicates a 
considerable disease burden for both individuals and society over time. 
Furthermore, patients had low HRQoL, with a substantial proportion of 
patients unable to work. Those who were working suffered marked 
impairment of their abilities in the workplace and lost a substantial 
amount of time per week to unproductivity as a result of their depres-
sion. Furthermore, impairment extended beyond patients’ work lives 
and into their overall everyday activities; the mean overall activity 
impairment was 73.3%. This highlights the far-reaching impacts of TRD 
(Heerlein et al., 2021a). 
Analysis of treatment patterns and outcomes over time further 
explored the impact of TRD on patients (Heerlein et al., 2021b). The 
findings suggested that, for most patients, current treatment options do 
not result in a clinically significant response. Yet, despite a lack of 
response, patients may remain on treatments for a prolonged period. The 
heterogeneity of treatment options identified in this analysis emphasizes 
the lack of clinical consensus (Heerlein et al., 2021b). 
The current paper supports the final objective, describing the HCRU 
of TRD patients from this cohort, and the estimated economic impact. 
While evidence indicates that MDD patients achieving remission have 
better long-term outcomes than those achieving response (Rush et al., 
2006; Mendlewicz, 2008), and there is some research to suggest that 
these differences are reflected in the HCRU (Yrondi et al., 2020), there 
remains a lack of research from broader European settings and a need for 
studies which translate HCRU into estimated economic impact. There-
fore, in this study, HCRU and its economic impact were analyzed and 
compared according to patient response and remission status. 
2. Methods 
2.1. Patients 
Male and female patients with TRD aged 18 to 74 years were 
recruited for the study by their treating physicians during routine clin-
ical practice. Eligible patients had a diagnosis of MDD according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and met 
the criteria for TRD, defined as failure to respond to at least two different 
oral antidepressant treatments, taken at an adequate dose and for a 
sufficiently long duration in the same MDE, in accordance with the 
Massachusetts General Hospital-Antidepressant Treatment Response 
Questionnaire (MGH-ATRQ). Patients were required to have a baseline 
MADRS score of ≥20 and were initiating a new antidepressant treatment 
strategy to treat the current MDE. In the context of this study, a new 
treatment strategy was defined as any pharmacological or non- 
pharmacological treatment prescribed to replace, or in addition to, the 
previous antidepressant treatment. Switches to a biosimilar or changes 
in dose were not considered as a new treatment. 
Patients were excluded if they had a prior diagnosis of psychotic 
disorder or MDD with psychotic features; displayed homicidal or sui-
cidal ideation or intent within 1 month prior to enrolment and/or had a 
positive response to Items 4 or 5 on the Columbia Suicide Severity 
Rating Scale (C-SSRS); a history of suicidal behavior within 1 year of 
enrolment of the study; moderate to severe substance or alcohol abuse, 
according to DSM-5 criteria, within 6 months of enrolment (excluding 
the use of nicotine and caffeine). All patients were required to provide 
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written informed consent and were excluded if, as per the opinion of the 
participating physician, they were not considered able to provide such 
consent. Approval for the study was provided by local ethics review 
boards, and the study was conducted in accordance with the Declaration 
of Helsinki. 
2.2. Study design 
This study was a prospective, multicenter, observational cohort 
study of patients with TRD, documenting outcomes in routine clinical 
practice across seven countries in Europe. Patients were enrolled from 
the United Kingdom, Italy, the Netherlands, Germany, Belgium, 
Portugal and Spain. The study design has been described in previous 
publications (Heerlein et al., 2021a, 2021b). It included baseline data 
collection, an observational period of 6–12 months and an extended 
observational period of up to 6 months after enrolment of the final pa-
tient. Scheduled data collection periods occurred at baseline, 6-monthly 
scheduled visits and at the end of the study or, in the case of premature 
end, at the end of the observation period. The study was closed for all 
patients when the last included patient reached a follow-up of 6 months, 
so that each included patient could have a minimum follow-up of 
approximately 6 months (Fig. 1). 
2.3. Study procedures and evaluations 
At baseline, data were collected on patient socio-demographics, 
disease history and current clinical characteristics, as well as details of 
all treatments used to treat the current MDE prior to study entry. The 
remission or response status of each patient was assessed at approxi-
mately 6 and 12 months after initiation of a new treatment at baseline. 
Response was defined as MADRS improvement from baseline ≥50% 
while remission was defined as MADRS score ≤10. As such, all patients 
who achieved remission were also responders, but not all patients who 
achieved response also achieved remission. 
HCRU data were collected from baseline to Month 6 (150–216 days 
after enrolment) using a HCRU questionnaire, completed by physicians 
on behalf of their patients. The questionnaire asked for the type and 
frequency/duration of visits, between baseline and Month 6, to outpa-
tient healthcare practitioner (HCP) consultations, inpatient hospital 
care, intensive care units (ICUs) and day/night clinics which were 
triggered by any clinically relevant worsening or improvement in the 
current depressive episode. The average cost (in Euros [€]) of HCRU per 
patient across the 6-month period from baseline to Month 6, was 
estimated via an economic impact model using published 2020 cost 
input data from Spain (Osakidetza, 2019; Boletín Oficial de la Región 
de, 2020), the second largest country cohort in the study. The cost input 
data for each healthcare resource type are presented in Supplementary 
Table 1. By applying these estimated costs to all instances of HCRU 
throughout the study, the estimated economic impact of HCRU over 6 
months was calculated for all patients, as well as separately for each of 
the responder/remitter groups, to assess the impact of these health 
states. 
2.4. Statistical analysis 
Descriptive analyses of HCRU from baseline to Month 6 were pre-
sented for all patients that had data recorded in the HCRU questionnaire 
up to Month 6. The number and percentage of patients (overall, and 
within each of the responder/remitter groups) using each healthcare 
resource at least once from baseline to Month 6 were calculated. The 
baseline and Month 6 visits were excluded from these calculations to 
ensure that differences in HCRU between groups could be adequately 
characterized (inclusion of these visits would lead to 100% of patients 
across all groups having at least one visit with a psychiatrist/neurolo-
gist). The mean, standard deviation (SD), median, minimum and 
maximum number of uses for each healthcare resource were also 
calculated. The exception was hospitalizations, for which the total 
length of stay was calculated, instead of number of uses. In cases where 
hospitalizations of an undefined duration were reported (i.e., start/end 
dates of admission were unavailable), the median duration of defined 
hospitalizations was imputed. 
The mean, SD, median, and minimum and maximum values were 
calculated for the estimated cost (€) of HCRU per patient (overall and 
within responder/remitter groups) over the 6 months starting at base-
line. The baseline and Month 6 visits were included in these calculations, 
since the estimation of economic impact by the model was facilitated if 
all patients had a cost input of >€0. Formal statistical analyses were 
conducted to evaluate whether differences between health states were 
significant: a generalized linear model was fitted, with log-link function 
and gamma distribution, in line with previously published methods 
(Flórez-Tanus et al., 2018). A two-sided p-value <0.05 was considered 
statistically significant. 
Fig. 1. Study design. *Baseline data were documented +/- 14 days of the date on which new treatment started. **Any clinically relevant worsening/improvement in 
the current MDE. ***HCRU data were analyzed from baseline to Month 6. HCRU: healthcare resource utilization; MDE: major depressive episode. 
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3. Results 
3.1. Baseline characteristics and response to treatment at month 6 
Since HCRU data were only collected for the first 6 months, only 6- 
month treatment outcomes are included here. Baseline characteristics 
for the total patient cohort, including prescribed treatments, as well as 
full details on outcomes of treatment up to Month 12, have been 
described elsewhere (Heerlein et al., 2021a, 2021b) Of the 411 patients 
that were included in the study, 306 had data recorded in the HCRU 
questionnaire up to Month 6 and were included in this analysis. For this 
sub-group of patients, the mean (SD) age of patients at baseline was 51.0 
(10.4) years and 61.1% (187/306) were female. The mean (SD) MADRS 
score was 31.9 (5.8), with 68.0% (208/306) of patients with moderate 
depression (MADRS score of 20–34) and 32.0% (98/306) with severe 
depression (MADRS score >34). The percentage of patients who had 
experienced two and three previous treatment failures was 55.2% 
(169/306) and 30.7% (94/306), respectively. At Month 6, 73.5% 
(225/306) of patients showed no response, 9.8% (30/306) showed 
response without remission and 16.7% (51/306) of patients achieved 
remission. 
3.2. Use of outpatient HCP consultations 
3.2.1. Response versus no response 
Overall, most patients across both non-responder and responder 
groups accessed at least one outpatient consultation from baseline to 
Month 6 (77.1% [172/223] and 78.3% [65/83], respectively). Howev-
er, the difference between the two groups was due to a greater pro-
portion of responders reporting at least one consultation with a 
psychiatrist/neurologist than non-responders. For other HCP types 
(general practitioners [GPs], psychologists, therapists and psychiatric 
nurses), higher proportions of non-responders accessed at least one 
outpatient consultation than responders (Supplementary Fig. 1A). 
With regards to number of consultations, from baseline to Month 6 
non-responders accessed all types of healthcare professionals with a 
greater mean frequency than responders. Non-responders accessed on 
average (mean [SD]) five times as many consultations with a GP (1.5 
Fig. 2. Mean number of outpatient HCP consultations between baseline and Month 6 (excluding baseline and Month 6 visits). A. Mean outpatient consultations 
stratified by response at Month 6. B. Mean outpatient consultations stratified by remission at Month 6. Response: MADRS improvement from baseline ≥50% or 
MADRS score >10; remission: MADRS score ≤10. GP: general practitioner; HCP: healthcare practitioner; MADRS: Montgomery-Åsberg Depression Rating Scale; SD: 
standard deviation. 
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[5.6] versus 0.3 [0.9]), and nine times as many consultations with a 
therapist and with a psychiatric nurse (respectively, 0.9 [6.8] versus 0.1 
[0.3] and 0.9 [5.6] versus 0.1 [0.6]) than responders. Despite a greater 
proportion of responders reporting at least one consultation with a 
psychiatrist/neurologist, the overall mean (SD) frequency of visits with 
this HCP group was also higher among non-responders than responders 
(3.8 [7.4] versus 2.8 [2.6]); Fig. 2A). 
3.2.2. Remission versus no remission 
In both non-remitter and remitter groups, most patients accessed at 
least one outpatient consultation, with a higher proportion among non- 
remitters than remitters (78.0% [199/255] versus 74.5% [38/51], 
respectively). Compared with patients who achieved remission, greater 
proportions of non-remitters reported at least one consultation with all 
HCP types except psychiatrists/neurologists (Supplementary Fig. 1B). 
Patients who did not achieve remission accessed, on average (mean 
[SD]), a higher number of consultations with all five types of healthcare 
professionals than remitters. In particular, non-remitters reported seven 
times as many GP consultations than patients in remission (1.4 [5.3] vs 
0.2 [0.9]). Further, despite a lower overall proportion of non-remitters 
accessing at least one consultation with a psychiatrist/neurologist 
than remitters, non-remitters had a higher mean (SD) frequency of 
consultations with this HCP type (3.7 [7.0] versus 2.5 [2.3], respec-
tively; Fig. 2B). 
3.3. Visits to hospital, ICU, and day/night clinics 
3.3.1. Response versus no response 
From baseline to Month 6, hospital admissions, and visits to ICU and 
day clinics were reported among both responders and non-responders. 
Fig. 3. Mean duration (number of days) or frequency of visits to hospital, ICU and day/night clinics between baseline and Month 6 (excluding baseline and Month 6 
visits). *For patients who did not specify the duration of hospital stay, the median duration for patients who did report start and/or stop dates (7 days) was imputed. 
A. Mean number of days/visits to healthcare settings stratified by response. B. Mean number of days/visits to healthcare settings stratified by remission. Response: 
MADRS improvement from baseline ≥50% or MADRS score >10; remission: MADRS score ≤10. ICU: intensive care unit; MADRS: Montgomery-Åsberg Depression 
Rating Scale; SD: standard deviation. 
K. Heerlein et al.                                                                                                                                                                                                                                
Journal of Affective Disorders 298 (2022) 442–450
447
At least one hospital admission was reported by 8.4% (7/83) of re-
sponders and 8.5% (19/223) of non-responders. Higher proportions of 
non-responders than responders reported visits to ICU (7.2% [16/223] 
versus 4.8% [4/83]) and day clinics (4.9% [11/223] versus 3.6% [3/ 
83], respectively). One non-responder (0.4% [1/223]), but no re-
sponders, accessed night clinics from baseline to Month 6 (Supplemen-
tary Fig. 2A). Further, non-responders reported a greater mean (SD) 
duration and/or frequency of visits than responders, overall (Fig. 3A). 
Specifically, patients who did not respond to treatment remained in 
hospital, on average, for more days (1.7 [8.6] vs. 1.1 [5.5]) and had 
more day clinic visits (0.1 [0.6] vs. 0.0 [0.3]), than responders. 
3.3.2. Remission versus no remission 
Overall, greater proportions of non-remitters reported at least one 
admission to hospital (9.0% [23/255] versus 5.9% [3/51]), to ICU 
(7.1% [18/255] versus 3.9% [2/51]) and to night clinics (0.4% [1/255] 
versus 0) compared to remitters. The reverse was true for day clinics, for 
which a lower proportion of non-remitters reported at least one atten-
dance than remitters (4.3% [11/255] versus 5.9% [3/51], respectively; 
Supplementary Fig. 2B). Compared to those who achieved remission, the 
mean (SD) duration of hospital stays of non-remitters was almost three 
times as long (1.7 [8.5] days versus 0.6 [3.1] days). Similar differences 
were not observed for ICU admissions or day/night clinics (Fig. 3B). 
3.3.3. Estimated cost of trd patient HCRU 
Over 6 months, the mean (SD) estimated cost of HCRU per TRD 
patient, regardless of response or remission status, was €1421.6 
(€3403.4; Table 1). When patients were stratified by response status, 
non-responders had a significantly higher mean (SD) estimated cost per 
patient than responders (€1575.4 [€3743.2] versus €1008.3 [€2216.2]; 
p = 0.002; Table 1). Differences in costs between health state groups 
were even more pronounced when patients were stratified by remission 
status. For non-remitters, the mean (SD) estimated HCRU cost per pa-
tient was €1548.2 (€3672.0) while the cost for a patient achieving 
remission was estimated to be €788.2 (€1292.4; p <0.001; Table 1). 
4. Discussion 
In this study, we assessed the HCRU of patients with TRD over 6 
months from the initiation of a new TRD treatment. The results support 
the findings of previously published studies, which suggest high HCRU 
among TRD patients (Jaffe et al., 2019; Johnston et al., 2019; Sussman 
et al., 2019). However, compared to a previous study of European pa-
tients with TRD, patients in the current study were found to report lower 
mean values for the number of GP consultations and overall HCP visits 
(Jaffe et al., 2019). This could reflect a wide variation in HCRU, possibly 
dependent on patient response to treatment as well as the specific 
healthcare system studied. 
Importantly, here it was found that HCRU was higher in patients who 
did not respond to treatment compared to those who did, with non- 
responders spending more days in hospital and having more outpa-
tient HCP consultations than patients who did respond to treatment. 
Comparisons according to remission status revealed even more pro-
nounced differences in HCRU. This aligns with previous work, which has 
shown that as the number of treatment failures rise the direct and in-
direct costs associated with TRD also increase (Johnston et al., 2019) 
and that as patients achieve response, remission and recovery, HCRU 
decrease (Yrondi et al., 2020). Such findings demonstrate the impor-
tance of achieving treatment success, not only for individual patients but 
also for healthcare providers and society as a whole. 
In line with these HCRU results, the economic impact analysis using 
previously published costing data from Spain showed that from baseline 
to Month 6, the mean cost per patient for responders was significantly 
less (on average €567.1 less; p = 0.002) than that of non-responders. The 
mean cost difference between non-remitters and remitters was even 
greater (mean costs were €760.0 less for remitters; p <0.001). Notably, 
although higher proportions of responders/remitters reported at least 
one consultation with psychiatrists/neurologists than non-responders/ 
non-remitters, the latter had a higher mean frequency of these consul-
tations. This suggests that, while responders and remitters were more 
likely to attend a psychiatrist or neurologist appointment, they were less 
likely to return within 6 months of starting a new treatment; they visited 
these HCPs less regularly than non-responders and non-remitters. 
Along with these direct costs of TRD to healthcare systems, previ-
ously reported results from this study have shown that TRD has a sub-
stantial indirect cost, too. Much of this expenditure is likely associated 
with the marked or extreme work impairment, substantial absenteeism 
and presenteeism, and reductions in overall activity and productivity 
both inside and outside of work (Heerlein et al., 2021a). Notably, pa-
tients achieving remission reported better functioning than 
non-remitters (Heerlein et al., 2021a). 
The substantial indirect costs associated with TRD have also been 
captured in other published works. In a US-based study, for example, 
patients with TRD were more likely than non-TRD MDD patients to 
claim government healthcare support offered to those whose employ-
ment status has changed (i.e. due to termination or reduced hours) 
(Amos et al., 2018). While TRD alone did not significantly impact 
employment termination, these findings indicate that the condition may 
be associated with higher rates of employment status change, for 
example transitioning from full-time to part-time employment. Such 
status changes may then in turn lead to additional indirect costs. Cor-
responding findings from European settings have also been reported. A 
registry study in Sweden examined TRD as a potential risk factor for 
being granted disability pension, demonstrating that TRD patients were 
twice as likely to be granted disability support than non-TRD MDD pa-
tients (Taipale et al., 2020), highlighting the additional strain placed on 
resources even relative to other patients with non-TRD MDD. Similarly, 
a registry study of patients living in Denmark found TRD patients to be 
twice as likely to receive disability pension than non-TRD depressed 
patients (Bang-Madsen et al., 2020). The data from Denmark also indi-
cated that TRD patients were three times more likely to prematurely 
leave the workforce than those without TRD, losing on average six 
work-years (Bang-Madsen et al., 2020). 
Together with the previously published findings of this study, these 
results demonstrate that the economic burden of TRD is not restricted to 
direct impacts of HCRU; rather, this condition can also result in sub-
stantial, indirect costs to patients and the wider societies of broad 
Table 1 
Economic analysis of HCRU over 6 months.  
Total healthcare costs, €* 
By response status at Month 6 All No response Response 
n 306 223 83 






Median 541.0 541.0 511.0 
Min, Max 253, 29,075 253, 29,075 253, 18,214 
Difference in mean cost between 
health states; p-value 
– 567.1; p = 0.002  
By remission status at Month 6 All No remission Remission 
n 306 255 51 






Median 541.0 569.0 476.9 
Min, Max 253, 29,075 253, 29,075 253, 8888 
Difference in mean cost between 
health states; p-value 
– 760.0; p<0.001  
* Includes baseline and Month 6 visits. The cost of the baseline visit was 
assumed to be equal to a first psychiatrist visit (€167); the cost of the Month 6 
visit was assumed to be equal to a follow-up psychiatrist visit (€86); the mini-
mum cost for all patient groups was equal to the sum of the baseline and Month 6 
visits (€253). HCRU: healthcare resource utilization; SD: standard deviation. 
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geographical regions. That said, it is important to consider when 
examining findings from different study cohorts that there are currently 
no rigid diagnostic criteria for TRD within DSM-5 or International 
Classification of Diseases (ICD-10). Similarly, lack of response to anti- 
depressive treatments exists on a continuum, and there is no clear cut- 
off point at which MDD transitions into TRD (Amos et al., 2018). As a 
result, the definition used can vary between different studies and make it 
challenging to define clear TRD/non-TRD patient subgroups. 
5. Limitations 
A limitation of the current study is its relatively small sample size, 
particularly for some of the included countries and some of the pre-
sented analyses. Additionally, as is the case for many real-world evi-
dence studies, there was no control group for comparison. Furthermore, 
while HCRU data were collected over a longer period, analysis was only 
completed on data from baseline to Month 6. Importantly, comparisons 
of patient subgroups were descriptive and did not take confounding 
variables into account. Moreover, economic costs were estimated based 
on local costs in Spain, though the cost structure may vary between 
countries and healthcare systems represented in the study. Finally, 
definitions of different types of healthcare appointment, such as a day 
clinic, may vary between the different European countries included in 
this study. This limitation is difficult to avoid when using real-world 
data from countries with different healthcare systems. 
6. Conclusion 
Overall, non-responders had greater HCRU and significantly greater 
associated costs than responders. Such differences were observed to an 
even higher degree in comparisons between non-remitters and re-
mitters. As such, the study highlights the economic impact of the con-
dition and the importance of effective treatments for patients, to reduce 
individual needs to access healthcare resources, thus also benefiting 
society as a whole. 
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Sapienza; Bertolino, Alessandro: Azienda Ospedaliero Universitaria 
Consorziale Policlinico di Bari; Bondi, Emi: Azienda Socio Sanitaria 
Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII); De 
Fazio, Pasquale: Azienda Ospedaliero Universitaria Mater Domini; 
Perugi, Giulio: Azienda Ospedaliero Universitaria Pisana; Petralia, 
Antonino: Azienda Ospedaliera Universitaria "Policlinico - Vittorio 
Emanuele" (Presidio Gaspare Rodolico); De Giorgi, Serafino: ASL Lecce; 
Clerici, Massimo: Azienda Socio Sanitaria Territoriale di Monza (Pre-
sidio San Gerardo); Bellomo, Antonello: Azienda Ospedaliero 
K. Heerlein et al.                                                                                                                                                                                                                                
Journal of Affective Disorders 298 (2022) 442–450
449
Universitaria Ospedali Riuniti di Foggia; Biondi, Massimo: Azienda 
Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La 
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